Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2000

View Archived Issues

At least 50% of patients experience clinical benefit with Vasogen's psoriasis candidate

Long-acting formulation of Amylin's diabetes Rx nears clinical trials

Positive phase IIa outcome reported for Xenova's XR-9576

Antisense compound from Isis enters phase III clinical testing

Pain Therapeutics begins phase II opioid pain medication trial

Cancer antigen discovery agreement signed by Genzyme Molecular Oncology and Purdue

HIV vaccine program at Panacos boosted by NIH grant

ArQule and Genome Therapeutics step up drug discovery collaboration

Cortex to study AMPAKINE stroke therapy under NIH grant

IND for hepatitis C gene fusion therapy submitted by Human Genome Sciences

New camptothecin derivative examined for safety, pharmacokinetics on various dosing schedules

MDR-reversing effects of MS-209 investigated in laboratory and animal experiments

TZT-1027 possesses additional antiangiogenic activity according to several recent studies

New squalene synthase inhibitor compares favorably to pravastatin and fenofibrate

NO-releasing paracetamol derivative exerts both analgesic and antiinflammatory effects

CHAP-based histone deacetylase inhibitors with antitumor activity presented at recent meeting

Novel theory of depression may lead to new therapeutic strategies

Sensory nerve sodium channel blocker shows potential in neuropathic pain

Pyrimidines prepared at AstraZeneca show inhibition of cell cycle kinases

Novel serotonergic diazole derivatives from AHP useful in depression and anxiety

Taisho presents new series of vasodilators

CHT-22: a new antitumor substance produced by Streptomyces

Sagami isolates novel antitumor agents from marine organism

Novel nicotinic receptor subtype-selective agents useful for CNS and GI disorders

Androgenic steroids with opposite configuration to natural products claimed by Azko Nobel

Inhibitors of protein-tyrosine-phosphatase in the Pharmacia pipeline

SB reports discovery of CCR3 receptor antagonists and potential applications thereof

The menace of antibacterial resistance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...